Glioblastoma Treatment: An Analysis of Recent Advances

Authors

Keywords:

Patient Care, glioblastoma, immunotherapy, neoplasms, therapeutics

Abstract

Glioblastoma, the most frequently treated malignant brain tumor in adults, presents a poor prognosis, with high recurrence and poor survival. Conventional treatment (surgery, radiotherapy, chemotherapy) is limited by its infiltrative nature and resistance induced by the tumor microenvironment. Current research focuses on understanding genetic and epigenetic changes to improve outcomes. Innovative approaches such as immunotherapy combined with virotherapy and T-cell therapy offer new hope, taking advantage of tumor-host interactions and immunogenic killing induced by oncolytic viruses. Additionally, immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4, along with cancer vaccines, are being explored to activate the adaptive immune system. These advances promise to improve patient care and survival rates and represent a significant change in their treatment. 

Downloads

Download data is not yet available.

References

Rodríguez-Mendoza B, Figueroa-González A, Cano-Herrera G, Gutierrez-Rosas LE, Romero-Torres CI, Victoria-Garcia LO, et al. Glioblastoma y su interacción con la neurogénesis [Glioblastoma and its interaction with neurogenesis]. Rev Neurol [Internet]. 2024 [citado: 27/12/24];79(10):279-287. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC11605900/

Cuba. Ministerio de Salud Pública (MINSAP). Anuario Estadístico de Salud 2023 [Internet]. La Habana: MINSAP. Dirección Nacional de Estadísticas de Salud; 2024 [citado: 10/12/2024]. Disponible en: https://temas.sld.cu/estadisticassalud/2024/09/30/anuario-estadistico-de-salud-2023/

Czarnywojtek A, Borowska M, Dyrka K, Van Gool S, Sawicka-Gutaj N, Moskal J, et al. Glioblastoma multiforme: las últimas técnicas diagnósticas y de tratamiento. Pharmacology. 2023 [citado: 27/12/24]; 108 (5): 423–431. Disponible en: https://doi.org/10.1159/000531319

Sadowski K, Jażdżewska A, Kozłowski J, Zacny A, Lorenc T, Olejarz W. Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches. Int J Mol Sci [Internet]. 2024 [citado: 27/12/24];25(11):5774. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC11172387/#sec3-ijms-25-05774

Roda D, Veiga P, Melo JB, Carreira IM, Ribeiro IP. Principios para el tratamiento del glioblastoma. Genes [Internet]. 2024 [citado: 27/12/24]; 15(4):501. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC11050118/#sec5-genes-15-00501

Liu Y, Zhou F, Ali H, Lathia JD, Chen P. Inmunoterapia para el glioblastoma: estado actual, desafíos y perspectivas futuras. Célula Mol Immunol [Internet]. 2024 [citado: 27/12/24]; 21(12):1354-1375. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC11607068/

Ríos Cabrera MM, Bello Rivero I, Cruz Rodríguez J. Desarrollo de la terapia farmacológica para tumores cerebrales de alto grado de malignidad. Rev Cubana Farm [Internet]. 2023 [citado: 27/12/24]; 56(3):e945. Disponible en: https://revfarmacia.sld.cu/index.php/far/article/view/945

Downloads

Published

2025-04-06

How to Cite

1.
Naranjo Lima S, Gálvez Vila RM. Glioblastoma Treatment: An Analysis of Recent Advances. Columna méd. [Internet]. 2025 Apr. 6 [cited 2025 Apr. 16];4(1):e294. Available from: https://revcolumnamedica.sld.cu/index.php/columnamedica/article/view/294

Issue

Vol. 4 (2025): Continuous publication

Section

Letter to the editor

License

Copyright (c) 2025 Shania Naranjo Lima, Richard Marcial Gálvez Vila Gálvez Vila

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

You are free of:

  1. Share copy and redistribute the material in any medium or format
  2. Adapt Remix, transform and build from material
  3. The licensor cannot revoke these freedoms as long as you follow the terms of the license

Under the following terms:

  1. Attribution - Oh, it's a good thing. You must give adequate credit , provide a link to the license, e indicate whether changes have been made . You can do it in any reasonable way, but not in such a way as to suggest that you or your use have the support of the licensor.
  2. Non-Commercial - Oh, it's a . You can't make use of the material with commercial purposes .
  3. No additional restrictions You can't apply legal terms or technological measures that legally restrict others from making any use permitted by the license.